Brief: Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment
24/04/2025 13:18
April 24 (Reuters) - PMGC Holdings Inc ELAB.O: NORTHSTRIVE BIOSCIENCES ANNOUNCES POSITIVE FDA RESPONSE SUPPORTING A SUBMISSION OF IND FOR A PHASE 2 CLINICAL TRIAL FOR EL-22 IN COMBINATION WITH GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT PMGC HOLDINGS INC - NORTHSTRIVE TO FILE IND APPLICATION IN 2025 Source text: ID:nGNX63yVMb Further company coverage: ELAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PMGC Holdings
See all newsBrief: PMGC Holdings Signs Non-Binding Letter Of Intent To Acquire Majority Stake In US-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, And Semiconductor Markets
Brief: PMGC Holdings Offers $7.8 Million In Common Stock To Streeterville Capital
NASDAQ RESUMED AT 12:33 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:28 PM
NASDAQ RESUMED AT 09:46 AM